基于《金匮要略》头风摩散结合摩法治疗偏头痛思路探究

偏头痛是临床常见头面部疾病,现在医学多采用特异性治疗药物跟非特异性止痛药物治疗。长期服药造成一定的并发症及不良反应,中西医结合治疗偏头痛是临床研究的重点。张仲景《金匮要略.中风历节病脉证并治》篇中初次记录头风摩散,该外治方的主要功效是用来治疗头风病,同时开创了摩顶膏法的先河。 摩法是最古老、最常用的手法之一。记载摩法的古代文献颇多,可追溯至《素问.病能》曰；“摩之切之。” 《素问.至真要大论》曰：“摩之、浴之。”并由此演绎出一系列实用手法。本文旨在探究摩法结合头风摩散治疗偏头痛的操作应用及其原理,进一步考究摩法与头风摩散结合治疗偏头痛的协同作用,以期对临床有一定指导意义。     

Assessment and characteristics of Erenumab therapy on migraine management

BackgroundMigraine is one of the neurological diseases that have a negative impact on subjects’ productivity and daily activity of patients. Introducing monoclonal antibodies as a valuable option for resolving the persistent problem of migraine is still under investigation. The current study aimed to evaluate the efficacy and safety profile related to Erenumab.MethodsA prospective study for clinical data collection and analysis from recruited therapy-refractory migraine subjects were carried through 6 months for each subject. All subjects received Erenumab 70 mg monthly. Each patient provided the clinical data monthly starting from 0 months and for the next 6 months. Migraine disability assessment (MIDAS) questionnaire was used for evaluation of the Erenumab efficacy every 3 months. In addition, data regarding adverse effects, migraine triggers, and the impact of previous COVID-19 on migraine severity were collected and analyzed.ResultsNinety subjects were recruited in the study. Erenumab injections resulted in a significant (p < 0.001) reduction in MIDAS score in the 3rd month compared with baseline, also this significance was continuous in the 6th month. In contrast, there was no significant difference in the 6th month compared with the 3rd. Previously infected COVID-19 subjects showed a higher severity of migraine attacks compared with non-infected subjects. Skin redness and local pain were the most common adverse effects 63.3%, 47.77% respectively associated with Erenumab.ConclusionUsing Erenumab therapy showed a great beneficial impact regarding the reduction of migraine-related disabilities. COVID-19 was related to the increased severity of migraine attacks.     

Inter-ictal assay of peripheral circulating inflammatory mediators in migraine patients under adjunctive cervical non-invasive vagus nerve stimulation (nVNS): A proof-of-concept study

Objective

To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.

儿童偏头痛验案2则

近年来,儿童偏头痛发病率逐年增高,多数医家从肝阳上扰、瘀血阻络等方面进行论治,张喜莲主任根据儿童"脾常不足、肝常有余"的生理特点,提出采用健脾燥湿豁痰、疏肝行气解郁等方法,辨证治疗儿童偏头痛效果满意。     

川芎-天麻配伍对川芎中2种成分在大鼠脑内药动学的影响

目的探讨川芎⁃天麻配伍对川芎中川芎嗪、阿魏酸在大鼠脑内药动学的影响。方法18只大鼠随机分成川芎组、川芎⁃天麻(1∶0.25)组、川芎⁃天麻(1∶1)组,每组6只,建立血瘀型偏头痛模型。灌胃给药后,于大鼠脑内插入微透析探针,收集不同时间点脑透析液,UPLC⁃MS/MS法检测川芎嗪、阿魏酸含有量,绘制血药浓度⁃时间曲线,计算药动学参数。结果与单味药组比较,配伍组2种成分T1/2[川芎⁃天麻(1∶1)组阿魏酸除外]、MRT0~∞、Cmax、AUC0~∞升高(P<0.05,P<0.01);川芎⁃天麻(1∶0.25)组两者T1/2、MRT0~∞、AUC0~∞高于川芎⁃天麻(1∶1)组(P<0.05,P<0.01),川芎嗪Cmax降低(P<0.05)。结论天麻可提高川芎中川芎嗪、阿魏酸脑组织吸收程度,延长作用时间,减缓消除速率,增加蓄积,其作用强度与天麻剂量有关。